危通笔记抗凝激素C

1.慢性肾病口服抗凝药物的收益与损害

2.集成皮质激素的CAP治疗Bundle策略对住院CAP患者预后之影响

3.抗胆碱能药物与痴呆风险

4.全美感染性疾病住院调查-

5.qSOFA评分在无法鉴别诊断患者中的应用以及与疑似感染及脓毒症的关联

6.REVEAL2.0预测肺动脉高压并与ESC/ERS风险评估策略的比较

7.反思心源性休克的缩血管药物：任何事情应以简为训，但不应过度简化

8.BMJ分析：输血的RBC储存时间不影响患者预后吗？

9.侵袭性真菌、细菌感染与非感染性炎症中可溶性甘露糖受体的鉴别价值——EPaNIC研究的二次分析

10.超声指导中心静脉穿刺：当前证据与临床推荐意见

11.AKI中中性粒细胞的活化：FINNAKI研究的二次分析

1.慢性肾病口服抗凝药物的收益与损害BenefitsandHarmsofOralAnticoagulantTherapyinChronicKidneyDisease:ASystematicReviewandMeta-analysis

JeffreyT.Ha,

DOI:10./M19-

Background:Effectsoforalanticoagulationinchronickidneydisease(CKD)areuncertain.

Purpose:ToevaluatethebenefitsandharmsofvitaminKantagonists(VKAs)andnon–vitaminKoralanticoagulants(NOACs)inadultswithCKDstages3to5,includingthosewithdialysis-dependentend-stagekidneydisease(ESKD).

DataSources:English-languagesearchesofMEDLINE,EMBASE,andCochranedatabases(inceptiontoFebruary);reviewbibliographies;andClinicalTrials.gov(25February).

StudySelection:RandomizedcontrolledtrialsevaluatingVKAsorNOACsforanyindicationinpatientswithCKDthatreportedefficacyorbleedingout